Bromocriptine/levodopa combined versus levodopa alone for early Parkinson's disease

Ramaker, CC; Hilten, JJ van

doi:10.1002/14651858.cd003634.pub2

Cited by 6 publications

(5 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The academic team agreed a priori that monotherapy with levodopa, dopamine agonists, catechol-O-methyl transferase (COMT) inhibitors, monoamine oxidase B (MAOB) inhibitors and anticholinergics all have evidence of efficacy with motor symptoms, at the expense of side effects. 21–25 The evidence is mostly from short term studies so longer term efficacy and adverse effects are uncertain. There is no good evidence regarding the optimal time for treatment initiation or dosage increase.…”

Section: Resultsmentioning

confidence: 99%

Priority setting partnership to identify the top 10 research priorities for the management of Parkinson's disease

et al. 2014

View full text Add to dashboard Cite

ObjectivesThis priority setting partnership was commissioned by Parkinson's UK to encourage people with direct and personal experience of the condition to work together to identify and prioritise the top 10 evidential uncertainties that impact on everyday clinical practice for the management of Parkinson's disease (PD).SettingThe UK.ParticipantsAnyone with experience of PD including: people with Parkinson's (PwP), carers, family and friends, healthcare and social care professionals. Non-clinical researchers and employees of pharmaceutical or medical devices companies were excluded. 1000 participants (60% PwP) provided ideas on research uncertainties, 475 (72% PwP) initially prioritised them and 27 (37% PwP) stakeholders agreed a final top 10.MethodsUsing a modified nominal group technique, participants were surveyed to identify what issues for the management of PD needed research. Unique research questions unanswered by current evidence were identified and participants were asked to identify their top 10 research priorities from this list. The top 26 uncertainties were presented to a consensus meeting with key stakeholders to agree the top 10 research priorities.Results1000 participants provided 4100 responses, which contained 94 unique unanswered research questions that were initially prioritised by 475 participants. A consensus meeting with 27 stakeholders agreed the top 10 research priorities. The overarching research aspiration was an effective cure for PD. The top 10 research priorities for PD management included the need to address motor symptoms (balance and falls, and fine motor control), non-motor symptoms (sleep and urinary dysfunction), mental health issues (stress and anxiety, dementia and mild cognitive impairments), side effects of medications (dyskinesia) and the need to develop interventions specific to the phenotypes of PD and better monitoring methods.ConclusionsThese research priorities identify crucial gaps in the existing evidence to address everyday practicalities in the management of the complexities of PD.

show abstract

Section: Resultsmentioning

confidence: 99%

Priority setting partnership to identify the top 10 research priorities for the management of Parkinson's disease

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Seven RCTs incorporating 1100 patients failed to show ant consistent difference between them, in terms of occurrence and severity of motor complications, scores of impairment and disability, or the occurrence of side effects. Like Baker et al [10] and Stowe et al [23] , Van Hilten et al [24] concluded that there was a role for the use of dopamine agonists in improving motor impairments in early PD, but only in those patients who could tolerate the drug. For this, although six RCTs were located with 850 patients, a metaanalysis was not possible as there were methodological problems and incomparable outcome indicators.…”

Section: Therapymentioning

confidence: 99%

“…Van Hilten et al ' s fi rst systematic review [24] on the use of bromocriptine in early PD compared a bromocriptine/levodopa combined therapy to levodopa alone. Seven RCTs incorporating 1100 patients failed to show ant consistent difference between them, in terms of occurrence and severity of motor complications, scores of impairment and disability, or the occurrence of side effects.…”

Section: Therapymentioning

confidence: 99%

A Literature Summary on Parkinson Disease

Corabian

Dennett

2010

Parkinson Disease

View full text Add to dashboard Cite

“…For years, BRO was primarily used in the treatment of Parkinson's disease . However, some studies have demonstrated that BRO treatment (10 mg/kg of body mass) in adult rats with obesity induced by diet for 4‐6 weeks prevents excessive body mass gain and improves comorbidities such as hyperglycaemia, hyperinsulinaemia, glucose intolerance, hypertension, hepatic steatosis and higher mitochondrial oxidative stress .…”

Section: Introductionmentioning

confidence: 99%

“…14 For years, BRO was primarily used in the treatment of Parkinson's disease. 15,16 However, some studies have demonstrated that BRO treatment (10 mg/kg of body mass) in adult rats with obesity induced by diet for 4-6 weeks prevents excessive body mass gain and improves comorbidities such as hyperglycaemia, hyperinsulinaemia, glucose intolerance, hypertension, hepatic steatosis and higher mitochondrial oxidative stress. 17,18 Thus, since 2009, BRO, formulated as a quickrelease tablet, was approved by the US Food and Drug Administration (FDA) as a supporting therapy for non-insulin-dependent diabetes mellitus with poor glycaemic control when associated with dietetic control and physical activity.…”

mentioning

confidence: 99%

Bromocriptine treatment at the end of lactation prevents hyperphagia, higher visceral fat and liver triglycerides in early‐weaned rats at adulthood

Peixoto-Silva

Moura

Carvalho

et al. 2017

Clin Exp Pharma Physio

View full text Add to dashboard Cite

Non-pharmacological early weaning (NPEW) leads offspring to obesity, higher liver oxidative stress and microsteatosis in adulthood. Pharmacological EW (PEW) by maternal treatment with bromocriptine (BRO) causes obesity in the adult progeny but precludes hepatic injury. To test the hypothesis that BRO prevents the deleterious changes of NPEW, we injected BRO into the pups from the NPEW model in late lactation. Lactating rats were divided into two groups: dams with an adhesive bandage around the body to prevent breastfeeding on the last 3 days of lactation and dams whose pups had free suckling (C). Offspring from both groups were subdivided into two groups: pups treated with BRO (intraperitoneal (i.p.) 4 mg/kg per day) on the last 3 days of lactation (NPEW/BRO and C/BRO) or pups treated with the vehicle (NPEW and C). At PN120, offspring were challenged with a high fat diet (HFD), and food intake was recorded after 30 minutes and 12 hours. Rats were killed at PN120 and PN200. At PN120, adipocyte size was greater in the NPEW group but was normal in the NPEW/BRO group. At PN200, the NPEW group presented hyperphagia, higher adiposity, adipocyte hypertrophy, hyperleptinaemia, glucose intolerance and increased hepatic triglycerides. These parameters were normalized in the NPEW/BRO group. In the feeding test, BRO groups showed lower HFD intake at 30 minutes than did their controls; however, at 12 hours, the NPEW group ate more HFD. The treatment with BRO can preclude some deleterious effects of the NPEW model, which prevented the development of overweight and its comorbidities.

show abstract

Bromocriptine/levodopa combined versus levodopa alone for early Parkinson's disease

Cited by 6 publications

References 32 publications

Priority setting partnership to identify the top 10 research priorities for the management of Parkinson's disease

Priority setting partnership to identify the top 10 research priorities for the management of Parkinson's disease

A Literature Summary on Parkinson Disease

Bromocriptine treatment at the end of lactation prevents hyperphagia, higher visceral fat and liver triglycerides in early‐weaned rats at adulthood

Contact Info

Product

Resources

About